Holen Sie sich die Stockscreener-App
2.945
0.51%
-0.015
Handel nachbörslich:
2.99
0.045
+1.53%
Schlusskurs vom Vortag:
$2.96
Offen:
$2.96
24-Stunden-Volumen:
2.88M
Relative Volume:
0.91
Marktkapitalisierung:
$881.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-241.99M
KGV:
-3.1366
EPS:
-0.9389
Netto-Cashflow:
$-133.64M
1W Leistung:
-5.00%
1M Leistung:
-28.17%
6M Leistung:
-5.00%
1J Leistung:
-13.13%
1-Tages-Spanne:
$2.90
$3.00
1-Wochen-Bereich:
$2.88
$3.3599
52-Wochen-Spanne:
$2.61
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
2.945 | 881.62M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Wedbush | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA) - The Globe and Mail
Sana Biotechnology, Inc. (SANA) Investor Outlook: A Biotech Player with a 171.89% Upside Potential - directorstalkinterviews.com
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com Australia
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com Canada
Sana Biotechnology | 8-K: Current report - Moomoo
Sana Biotechnology updates corporate presentation, targets SC451 IND and unveils in vivo CAR T progress - tradingview.com
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - The Conway Daily Sun
Sana Biotechnology to Present at September 2026 Investor Conferences - The Manila Times
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer PATEL DHAVALKUMAR DHIRAJLALmoomoo - Moomoo
Sana (SANA) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison; Post-Report: Shares Finish 4.55% Higher in the Latest SessionRevenue Report - vinanet.vn
Sana (SANA) Outlook: Moves 4.55% Higher to $3.91 in Latest Trading; the Supplied Trading Band Runs From $3.71 to $4.11 in the Latest SessionOvervalued Signals - dars.gov.et
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention - Kalkine Media
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - Sahm
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2%Time to Sell? - MarketBeat
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely? - Moomoo
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9%Still a Buy? - MarketBeat
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses? - Sahm
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - The Globe and Mail
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - MarketBeat
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - MarketBeat
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SANA Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.19%Low Estimate Range - careplusvn.com
SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget
Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - MarketBeat
Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net
Sana: Q2 Earnings Snapshot - KVUE
Sana Biotechnology | 8-K: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Moomoo
BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sana Biotechnology Inc-Aktie (SANA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 07 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
7,968,596 |
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):